Open AccessTafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials
Author(s) -
В. С. Косоруков,
Г. Р. Абузарова,
Е. Р. Захарочкина,
O. Yu. Gamzeleva,
K. A. Yatsenko
Publication year - 2022
Publication title -
opuholi golovy i šei
Language(s) - English
Resource type - Journals
eISSN - 2411-4634
pISSN - 2222-1468
DOI - 10.17650/2222-1468-2022-12-2-89-107
Subject(s) - tolerability , medicine , adverse effect , pharmacokinetics , clinical trial , dosing , phases of clinical research , analgesic , subcutaneous injection , opioid , pharmacology , receptor